Abstract
Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.
Keywords: Inhaled corticosteroids, cystic fibrosis, adverse effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Inhaled Corticosteroids In Treatment of Cystic Fibrosis
Volume: 11 Issue: 3
Author(s): Ela Erdem and Refika Ersu
Affiliation:
Keywords: Inhaled corticosteroids, cystic fibrosis, adverse effects
Abstract: Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.
Export Options
About this article
Cite this article as:
Erdem Ela and Ersu Refika, Inhaled Corticosteroids In Treatment of Cystic Fibrosis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012; 11 (3) . https://dx.doi.org/10.2174/1871523011202030206
DOI https://dx.doi.org/10.2174/1871523011202030206 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Animal Models to Study Plaque Vulnerability
Current Pharmaceutical Design Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Quaternary Structure, Substrate Selectivity and Inhibitor Design for SARS 3C-Like Proteinase
Current Pharmaceutical Design Mucosal Adjuvants
Current Pharmaceutical Design Physiological and Pathophysiological Roles of ATP-Sensitive K+ Channels in Vascular Smooth Muscle
Vascular Disease Prevention (Discontinued) Extracts of Bacopa monnieri (L) Pennell Down-Regulate the Expression of Leukotriene C<sub>4</sub> Synthase mRNA in HL-60 Cells and Suppress OVAInduced Inflammation in BALB/c Mice
Current Bioactive Compounds Targeting Apoptosis to Treat Multiple Sclerosis
Current Drug Discovery Technologies Anti-Saccharomyces Cerevisiae as Unusual Antibody in Autoimmune Polyglandular Syndrome Type III: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Idiotype Vaccines for Human B-Cell Malignancies
Current Pharmaceutical Design Impact of Epigenetic Alterations in the Development of Oral Diseases
Current Medicinal Chemistry Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review
Letters in Drug Design & Discovery Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Synthesis and Biological Interest of Structured Docosahexaenoic Acid–Containing Triacylglycerols and Phospholipids
Current Organic Chemistry Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
Current Medicinal Chemistry Pharmacokinetics and Pharmacokinetic Variability of Heroin and its Metabolites: Review of the Literature
Current Clinical Pharmacology Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial
Current Pharmaceutical Design Changes of Drug Metabolizing Enzymes in the Liver of Male Sheep Exposed to either Cypermethrin or Dimethoate
Drug Metabolism Letters Role of Nitrosative Stress and Activation of Poly(ADP-ribose) Polymerase-1 in Cardiovascular Failure Associated with Septic and Hemorrhagic Shock
Current Vascular Pharmacology